Viewing affirmative mentions of localization of IL2 (H. sapiens)

Full-text article links are indicated by after the article reference.

Document Target Regulator Anatomy Sentence
Bödeker et al. (1981)IL-2Optimal IL-2 release was found at a low speed of stirring allowing circulation of the medium without suspending the agglutinated cells, and at an oxygen concentration of about 30-45% of saturation.
Foa et al. (1992)IL2The constitutive secretion of IL2 by the tumour cells leads to a reduced or abrogated tumorigenicity in several different tumour models.
Kaplan et al. (1988)IL-2Thus, cells with the potential of producing and secreting IL-2 upon stimulation possessed the surface epitopes of the lymphokine and cells either actively secreting IL-2 or without the potential for secretion were negative for surface expression.
Conradt et al. (1988)IL-2During the first 30 hours of incubation cells secrete only the nonglycosylated IL-2 M form of the lymphokine, the glycosylated forms IL-2 N1,2 being detected only after prolonged culture times (30-48 h).
Conradt et al. (1988)IL-2After recultivation of cells for a second 48 h period (without additional mitogen), the glycosylated and nonglycosylated IL-2 forms are secreted at a constant ratio of 7:3 throughout.
Uchiyama et al. (1993)IL-2IL-2 gene was transfected into three human melanoma cell lines; secretion of IL-2 from stable transfected cells was confirmed by enzyme-linked immunosorbent assay.
Kalashnikova and Pukhal'ski? (1993)IL-2Mechanisms of IL-2 release modification by Dx are discussed.
Marijani et al. (2007)IL-2The bioactivity of ciclosporin MDI formulations was evaluated by determining the ciclosporin-mediated inhibition of interleukin-2 (IL-2) release from human Jurkat cells stimulated with phorbol 12-myristate 13-acetate (PMA).
Stopeck et al. (1998)IL-2IL-2 secretion by tumor cells persisted for at least 30 days post-transfection and was unaffected by freeze thawing or irradiation to 8000 rads.
Stopeck et al. (1998)IL-2Enzyme-linked immunoabsorbent analysis of the amount of IL-2 secreted into the medium by transfected tumor cells correlated with the percentage of tumor cells expressing intracellular IL-2 as measured by flow cytometry.
Belli et al. (1997)interleukin-2From January 1994 to July 1996 we immunized metastatic melanoma patients with HLA-A2-compatible, interleukin-2 (IL-2)-secreting, immunogenic melanoma lines in an attempt to induce a systemic reaction that might also affect distant melanoma lesions.
Belli et al. (1997)IL-2These results indicate that vaccination with cells bearing the appropriate antigens and releasing IL-2 locally can produce weak clinical responses, but also indicate that better results may be achieved through modifications of the vaccine, the schedule of immunization and/or a more appropriate selection of patients.
Niu et al. (1996)IL2In order to investigate the antitumor effect of IL2 gene transfected tumor vaccine, gene transfected tumor cells which secrete IL2 in a comparatively sustained manner must be obtained.
Niu et al. (1996)IL2IL2 secretion of B16-IL2 was comparatively stable for a period of 6 months with the highest production rate of 53u/ml.
Sasagawa et al. (2006)IL-2Simultaneous measurement of secreted IL-2 by ELISA and cell viability by the XTT assay showed that the 95:5 ethanol/water extract of E. purpurea was both IL-2 suppressive and cytotoxic at 50 and 100 microg/mL.
Castignolles et al. (1994)interleukin-2Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides.
Viviani et al. (1992)IL-2Alterations of both IL-2 and melatonin secretion have been reported in cancer patients.
Froelich et al. (1988)interleukin-2Cultures from two groups of aged donors, recruited respectively from our ambulatory clinic and a nursing home, incorporated less tritiated thymidine (3H-TdR) and secreted less interleukin-2 than did young donors.
Froelich et al. (1988)IL-2It was also shown that the amounts of soluble IL-2 receptors that were released into the supernatants by mitogen stimulated cells did not differ for the aged and young donors.
Uchino et al. (2002)IL-2IL-2 release from the cells was enhanced by SQOOH and increased at a non-cytotoxic dose.
Cadée et al. (2002)interleukin-2In this study, the release of recombinant human interleukin-2 (rhIL-2) from methacrylated dextran (dex-MA) and (lactate-)hydroxyethyl methacrylated dextran (dex-(lactate-)HEMA) hydrogels with varying crosslink density was investigated.
Cadée et al. (2002)rhIL-2The protein release profiles both the non-degradable and degradable dextran-based hydrogels showed that with increasing crosslink density of the gel, the release of rhIL-2 decreases.
Cadée et al. (2002)rhIL-2From dex-MA hydrogels with an initial water content above 70%, the rhIL-2 release followed Fickian diffusion, whereas from gels with an initial water content of 70% or lower the protein was fully entrapped in the hydrogel meshes.
Cadée et al. (2002)rhIL-2In contrast with non-degradable dex-MA hydrogels, degradable dex-lactate-HEMA gels with comparable network characteristics (degree of methacrylate substitution and initial water content) showed an almost zero-order, degradation controlled release of rhIL-2 in a time period of 5-15 days.
Cadée et al. (2002)rhIL-2Importantly, rhIL-2 was mainly released as monomer from the hydrogels and with good retention of its biological activity.
Voss et al. (1989)IL-2In 12 patients receiving high-dose IL-2 for the treatment of various malignant neoplasms, the levels of IL-2 receptor released into the serum rose dramatically during the IL-2 infusion, and then fell following cessation of the IL-2 infusion.
Voss et al. (1989)IL-2This heightened release of IL-2 receptor into the serum occurred during the episodes of profound lymphopenia that developed within hours after patients began an IL-2 infusion.
Lindqvist et al. (1987)IL-2A significant positive correlation between blockage of induced cell aggregation by antibody 60.3 and reduction in IL-2 release was observed.
Lindqvist et al. (1987)IL-2The addition of interleukin-1 (IL-1) restored IL-2 secretion in PHA-treated, but not in 4-beta-phorbol 12, 13-dibutyrate [P(Bu)2]-treated, cells in the presence of this antibody.
Cignetti et al. (1994)IL2These findings have prompted investigations into whether human tumor cells may be transduced with the IL2 gene and whether tumor cell lines could be engineered to release IL2.
Cignetti et al. (1994)IL2Messenger RNA expression of the IL2 gene was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) and productive IL2 release using a human IL2 assay and an enzyme-linked immunosorbent assay kit.
Cignetti et al. (1994)IL2The amounts of IL2 constitutively released by the engineered neoplastic cells ranged between 1 and 11 U/mL of IL2 produced from 10(6) cells in 72 hours.
Cignetti et al. (1994)IL2In nude mice injected with various IL2-producing ST4 clones, tumor growth associated inversely with the amounts of IL2 secreted by the leukemic cells.
Babkin et al. (2008)IL-2The authors show the capacity of CV-1 cells infected with the recombinant vaccinia virus VV-SIL2 to secrete human IL-2 into the culture medium.
Liu and Rosenberg (2001)IL-2Furthermore, an Ab reactive with the alpha-chain of IL-2R complex reduced the viability mediated by IL-2 secretion of the IL-2 transductants.
Vives et al. (1987)IL-2A similar level of IL-2 secretion in both populations was also obtained when they were stimulated with a combination of phorbol ester plus ionophore.
Pawelec et al. (1989)IL-2Tolerised clones which had lost autocrine proliferative capacity and had lost the ability to secret IL-2 nevertheless retained the ability to secrete the other lymphokines.
Nordmann et al. (1989)interleukin 2 proteinThis novel quantitative kinetic analysis revealed that, independent of the absence or presence of cyclosporin A, interleukin 2 protein is synthesized at a rate of approximately 1.3 molecules per molecule of interleukin 2 mRNA per second and secreted within 2 h after it is synthesized and that its half-life in the supernatant is approximately 10 h.
Gonwa et al. (1985)interleukin-2Available evidence suggest that it interferes with the secretion of interleukin-2.
Benjamin et al. (1989)IL-2Teleocidin (10 ng/ml) triggered IL-2 secretion in 7/8 (87%) EBV-negative lymphoma cell lines of American origin and in 6/6 (100%) normal lymphoblastoid cell lines, but in only 1/6 (16%) EBV-positive tumor cell lines of American origin.
Benjamin et al. (1989)IL-2IL-2 secretion was not detected in control supernatants.
Benjamin et al. (1989)IL-2IL-2 secretion correlated with the induction of IgM secretion and was linked to both EBV status and karyotype.
Benjamin et al. (1989)IL-2The cell lines were also found to constitutively express IL-2 receptors detected by anti-tac monoclonal antibody, and to secrete soluble IL-2 receptors measured by ELISA.
Wilkinson and Euhus (2003)IL-2A fresh primary breast cancer culture, transduced with Ad5.CMV-IL2 at an MOI of 1000:1, secreted IL-2 at 15 ng/24 h 1 day after transduction and peaked at 85 ng/24 h 5 days after transduction.
Duprez et al. (1985)IL-2We describe a human tumor cell line regulated by an autocrine secretion of the growth factor interleukin 2 (IL-2).
Meuer et al. (1984)IL-2These results suggest that induction of IL-2 receptor expression but not IL-2 release occurs in the absence of T3-Ti receptor cross-linking.
Lantz et al. (1991)IL-2EBV cell-lines (LCL) and E- cells as stimulator cells for limiting dilution analysis (LDA) of alloreactive IL-2-secreting cells (IL-2-SC) and cytotoxic precursors (CTLp).
Lantz et al. (1991)IL-2Consequently, we undertook a systematic comparison of the efficiency of both types of cell for the LDA of alloreactive IL-2-secreting cells (IL-2-SC) and cytotoxic precursors (CTLp).
Lantz et al. (1991)IL-2We show that LCL are stronger stimulator cells both for IL-2 secretion and for cytotoxicity induction.
Hank et al. (1999)IL-2In patients receiving comparable IUs of the two preparations, HLR IL-2 induced the release of more soluble IL-2 receptor alpha into the serum than Chiron IL-2.
Theobald et al. (1989)IL-2HTL-p stimulated with allogeneic Epstein-Barr virus-transformed B lymphoblastoid cell lines (EBV-LCL) in the presence of exogenous recombinant IL-2 (r-IL-2) clonally developed into IL-2 secreting effector cells when restimulated against the original stimulating alloantigen.
Theobald et al. (1989)IL-2Frequencies of alloreactive IL-2-secreting HTL-p ranged from 1/100 to 1/800.
Theobald et al. (1989)IL-2In (clonal) segregation analyses the vast majority of IL-2-secreting progenies (80%) were specific for the original stimulating alloantigen.
Goronzy et al. (1987)IL 2Although all clones analyzed expressed IL 2 receptors and secreted IL 2 after non-antigenic activation, one subset of clones did not proliferate in response to the same non-antigenic signals.
Kopantzev et al. (1998)IL-2More importantly, intravenous immunization of animals with irradiated, IL-2 secreting cells from either line leads to significant protection from challenge with highly metastatic parental cells.
Nierle et al. (1993)IL-2By using limiting dilution (LD) and clonal specificity analyses, we investigated in 14 patients with and without acute GVHD after non-T-depleted HLA-identical sibling BMT whether posttransplant host-reactive mH-specific interleukin-2 (IL-2)-secreting Th are involved in the development of clinically significant acute GVHD and the establishment of tolerance.
Weiss et al. (1987)IL 2Studies of the time-dependent requirements for the two stimuli required for activation revealed that simultaneous stimulation with both Con A and PMA is required for 2 to 4 hr for the cell to commit itself to activation, as measured by the appearance of secreted IL 2.
Patel et al. (1994)interleukin-2Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors.
Patel et al. (1994)IL-2This study aimed to determine the feasibility of producing patient-specific, interleukin-2 (IL-2)-secreting tumor cell vaccines for the treatment of metastatic melanoma.
Patel et al. (1994)IL-2Multiple infections increased the level of IL-2 secretion to 5,000 units/10(6) cells.48 hr.
Patel et al. (1994)IL-2IL-2 secretion from infected cultures was maintained following cryopreservation and x-irradiation.
Patel et al. (1994)IL-2These data demonstrate that heterogeneous tumor cell populations secreting IL-2 can be generated from individual patients to be used as autologous, irradiated cell vaccines.
Smith et al. (1985)interleukin 2Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector.
Smith et al. (1985)IL-2 polypeptideCells infected with recombinant virus produced high levels of Mr 15,500 IL-2 polypeptide, the majority of which was secreted into the culture medium during infection.
Pizzato et al. (1998)IL-2Transduced glioma cells were sensitive to ganciclovir and secreted around 1000 U/ml IL-2 in the culture supernatants.
Bost et al. (1988)IL-2The homologues are six amino acids in length corresponding to the carboxy terminus of gp41, Leu-Glu-Arg-Ile-Leu-Leu (LERILL), and residues 14-19 of secreted IL-2, Leu-Glu-His-Leu-Leu-Leu (LEHLLL).
Takimura et al. (1997)IL-2Biologically active human IL-2 was produced efficiently and secreted directly into the medium by B. brevis.
Zhou et al. (1997)IL-2The amounts of IL-2 constitutively released by the engineered neoplastic cells ranged from 20 to 131 U/ml of IL-2 produced from 10(6) cells in 24 hours.
Gelfand et al. (1987)IL2An increase in [Ca2+]i is critical for IL2 secretion in contrast to the requirements for IL2 receptor expression and IL2-IL2 receptor interaction.
Gelfand et al. (1987)IL2Influx of Ca2+ from the extracellular milieu appears essential for the induced increase in [Ca2+]i associated with IL2 secretion.
Gelfand et al. (1987)IL2These increases in [Ca2+]i, which are correlated with the degree of lymphoproliferation and IL2 secretion, are sensitive to changes in membrane potential.
Huang et al. (2002)IL-2ELISA analysis revealed that ST treatment generally showed negative effects on the IL-2 secretion of HPBMc in vitro.
Huang et al. (2002)IL-2The time-effect analysis (ST 1 mg/L) showed that inhibiting effects of ST on IL-2 secretion of HPBMc could be seen to a variable degree from 1 to 64 h after ST treatment, while a significant time-effect correlation could be found from 8 to 64 h (r = 0.822, P < 0.05).
Huang et al. (2002)IL-2The results obtained in present study showed that ST has certain inhibiting effects on the secretion of IL-2 of HPBMc in vitro.
Winandy et al. (1998)IL-2This technique relies on an indirect measurement of interleukin-2 (IL-2) secreted by the HTLp, as assessed by the proliferation of an IL-2 dependent cell line.
Alosco et al. (1994)IL-2Cell lines secreting 0.5-20 Cetus units/ml of IL-2 were generated.
Alosco et al. (1994)IL-2Growth arrest also correlated strongly with the amount of IL-2 secreted by the tumor cells.
Alosco et al. (1994)IL-2The local secretion of IL-2 by the transduced cell line will abrogate the tumorigenicity of the parental cell line as well as an allogeneic tumor.
Lai et al. (1989)IL2The cellular IL2 receptor expression and soluble IL2 receptor release did not differ between the patients and healthy controls.
Lai et al. (1989)IL2The mitogen-stimulated cellular IL2 receptor expression, IL2 receptor release, and IL2 production did not differ between patients with or without carbimazole therapy.
Rossi et al. (1988)IL2Phorbol ester significantly increased the IL2 secretion in both the PB and the BM of B-CLL patients.
Rossi et al. (1988)IL2However, IL2 secretion increased in the BM cells from B-CLL patients after addition of indomethacin or prior irradiation, in a similar way to that observed in PB and BM of normal controls, suggesting an apparent normal control of the IL2 production in BM from B-CLL patients.
Alileche et al. (1993)interleukin 2Human melanoma cell line M14 secretes a functional interleukin 2.
Alileche et al. (1993)IL2In the M14 melanoma cell line, we observed the appearance of the 0.9 kb transcript specific for the IL2 gene, 72 h after subculture, and the secretion of a biologically active IL2 which specifically sustains the proliferation of the IL2 dependent murine lymphoid cell line CTLL2.
Rezai et al. (1990)IL-2Both secreted IL-2 and messenger RNA coding for IL-2 were inhibited by histamine.
Valentine et al. (1985)IL-2Reactive hybridomas also released IL-2 following coculture with allogeneic EBV-infected cells when those cells shared HLA-DR antigens of the primary parental cells.
Valentine et al. (1985)IL-2In contrast, stimulator cells with no shared HLA-DR or without evidence of EBV infection never induced IL-2 release.
Vine et al. (1989)IL2Fixed AC and IL1 beta, on the other hand, caused a small increase in the frequency of immobilized 64.1-activated T4 cells that secreted IL2.
Bödeker and Mühlradt (1983)IL-2The duration of IL-2 release was found to be limited by low molecular weight inhibitory substances.
Bödeker and Mühlradt (1983)IL-2These substances reversibly inhibited further IL-2 release at later times.
Bödeker and Mühlradt (1983)IL-2To overcome the limitation of IL-2 release by inhibitors, a procedure of repeated induction was developed.
Okada et al. (1981)IL-2One of the established hybrid clones (24-A) secreted human interleukin-2 (IL-2).
Branda et al. (1989)IL-2However, CQS did not block secretion of IL-2 into culture supernatant fractions by human PBMNCs.